Patients with advanced cervical cancer receive a variety of second-line treatment regimens, according to a study published in Gynecologic Oncology.

Researchers evaluated real-world treatment patterns in a cohort of patients with recurrent or metastatic cervical cancer. 

The results showed that most patients received standard first-line therapy, but second-line treatment regimens varied, and 52% of patients did not receive any second-line treatment. 

Continue Reading

For this retrospective study, researchers analyzed data from The US Oncology Network. The data encompassed 262 patients with recurrent or metastatic cervical cancer who had received first-line systemic therapy from September 2014 through December 2019. Patients were followed through December 2020. 

The mean age at the start of first-line treatment was 53 years, and 54.6% of patients had an ECOG performance status of 0-1. Most patients had squamous cell histology (68.3%) or adenocarcinoma (23.3%). Some patients had received radiotherapy (63.4%) or had undergone surgery (37.0%) prior to the index date.

The most common first-line systemic treatments were platinum doublet chemotherapy plus bevacizumab (66.4%) or doublet chemotherapy only (23.7%). The median time to discontinuation of first-line therapy was 3.5 months.

All 262 patients completed first-line treatment, and 125 (47.7%) went on to receive second-line therapy. Second-line regimens varied, with 39 patients receiving combination therapy, 35 receiving pembrolizumab alone, 5 receiving bevacizumab alone, 40 receiving other monotherapy, and 6 enrolling on a clinical trial.

There were 137 patients (52.2%) who did not initiate second-line treatment. In this group, 55 patients discontinued first-line treatment and died, 31 had disease progression on first-line therapy, 23 completed first-line treatment with no disease progression, 25 were lost to follow-up, and 3 were still on first-line therapy at last follow-up.

These findings suggest that most patients with recurrent or metastatic cervical cancer receive the current standard of care as first-line treatment, but many do not proceed to second-line therapy, and there is “no clear single choice of therapy” in the second line, the researchers concluded.

Disclosures: This study was supported by Seagen, Inc. Some study authors declared affiliations with biotech, pharmaceutical, and/or device companies. Please see the original reference for a full list of disclosures.


Alholm Z, He D, Ting J, et al. Real-world treatment drop-off among recurrent or metastatic cervical cancer patients: A US community oncology-based analysis. Gynecol Oncol. Published online July 29, 2022. doi:10.1016/j.ygyno.2022.07.026

This article originally appeared on Cancer Therapy Advisor